Jefferies Financial Group Reaffirms “Hold” Rating for Bausch Health Companies (NYSE:BHC)

Bausch Health Companies (NYSE:BHC)‘s stock had its “hold” rating restated by research analysts at Jefferies Financial Group in a research note issued on Thursday,Benzinga reports. They currently have a $8.00 target price on the stock, down from their prior target price of $12.00. Jefferies Financial Group’s price objective indicates a potential upside of 22.23% from the company’s current price.

BHC has been the subject of a number of other reports. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada dropped their price objective on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. Finally, Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.42.

Bausch Health Companies Stock Performance

Bausch Health Companies stock traded down $0.80 during midday trading on Thursday, reaching $6.55. The company’s stock had a trading volume of 3,312,779 shares, compared to its average volume of 3,329,603. The firm has a market capitalization of $2.37 billion, a PE ratio of -13.64 and a beta of 0.68. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46. The stock’s 50 day simple moving average is $7.72 and its 200 day simple moving average is $7.46.

Hedge Funds Weigh In On Bausch Health Companies

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new stake in Bausch Health Companies during the 4th quarter worth $180,000. Aigen Investment Management LP bought a new stake in Bausch Health Companies in the fourth quarter valued at about $180,000. Charles Schwab Investment Management Inc. boosted its holdings in Bausch Health Companies by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company’s stock worth $10,375,000 after purchasing an additional 14,558 shares during the period. Handelsbanken Fonder AB raised its stake in Bausch Health Companies by 18.4% during the fourth quarter. Handelsbanken Fonder AB now owns 65,100 shares of the company’s stock worth $525,000 after acquiring an additional 10,100 shares during the period. Finally, Principal Securities Inc. boosted its position in Bausch Health Companies by 39.7% during the 4th quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock valued at $155,000 after purchasing an additional 5,464 shares during the period. Hedge funds and other institutional investors own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.